文献速递临床生化分子诊断临床免疫

肺癌中MLKL相关坏死性凋亡生物标志物的电化学生物传感器:从实验室到临床检验

Electrochemical biosensors for MLKL-related necroptosis biomarkers in lung cancer: From bench to clinical laboratory.
PubMed 文献 · Clin Chim Acta · 2026-04-20

本综述聚焦肺癌中混合谱系激酶结构域样蛋白(MLKL)及其磷酸化形式(pMLKL)相关坏死性凋亡生物标志物,系统分析电化学生物传感器在血清、血浆和支气管肺泡灌洗液(BALF)等临床标本中的检测进展。文章重点讨论电极界面设计、生物识别元件与信号放大方法,并对比传统技术的局限,提出AI辅助信息学框架整合多模态MLKL标志物 panel。

要点

  • MLKL/pMLKL是肺癌坏死性凋亡的关键执行分子与候选生物标志物。
  • 电化学生物传感器可在血清、血浆和BALF中快速灵敏检测MLKL相关靶标。
  • AI辅助信息学框架有望桥接实验室研究与临床检验应用。

核心结论

  • 电化学生物传感是开发肺癌MLKL特异性坏死性凋亡诊断的独特且有前景的途径。

研究设计与样本

  • 本文为叙述性综述,聚焦以MLKL为中心的坏死性凋亡生物学及电化学生物传感在临床检验中的应用缺口。
  • 综述分析了MLKL/pMLKL相关生物标志物及电化学生物传感器在血清、血浆和BALF等临床相关标本中的检测进展。
  • 文中重点关注电极界面设计、生物识别元件(抗体、适配体、分子印迹聚合物)及信号放大方法。

主要发现

  • 电化学生物传感器已成为在复杂生物样本中快速、灵敏检测疾病相关靶标的有前景分析平台。
  • 传统技术如ELISA、免疫组化和PCR在检测MLKL相关标志物时存在局限性,文中对此进行了批判性分析。
  • 提出一个信息学框架,聚焦AI辅助信息学以整合多模态MLKL生物标志物panel,桥接实验室研究与临床应用。

临床怎么用

  • 可关注电化学生物传感器在血清、血浆和BALF中检测MLKL/pMLKL的临床转化潜力。
  • 在方法学选择上,需权衡电化学生物传感与传统ELISA、免疫组化、PCR的适用场景与局限。
  • AI辅助信息学框架可作为整合多模态MLKL标志物panel、连接实验室与临床检验的参考思路。

局限性

  • 本文为综述,未报告原始研究的具体样本量、阈值或诊断性能数值。
  • 电化学生物传感器在临床检验中的实际应用仍面临从实验室到临床转化的分析缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung cancer continues to be a leading cause of cancer-related mortality globally, necessitating the development of enhanced biomarkers for early detection and ongoing disease monitoring in clinical practice. Current diagnostic methodologies predominantly rely on imaging and tissue biopsy, which may not sufficiently capture the dynamic molecular alterations occurring during disease progression. Necroptosis is an inflammatory form of regulated cell death that is pathologically relevant in lung cancer. Mixed lineage kinase domain-like protein (MLKL) and its phosphorylated form (pMLKL) have become molecular executors and targets of biomarker clinical applications. In contrast to the available reviews that cover biosensor technologies and regulated cell death in general, this review is uniquely focused on MLKL-centric necroptosis biology and electrochemical biosensing as an analysis gap in clinical laboratory applications. Electrochemical biosensors have emerged as promising analytical platforms for the rapid and sensitive detection of disease-associated targets in complex biological samples. This review critically analyzes recent developments in MLKLs- and pMLKL-related necroptosis biomarkers and electrochemical biosensing approaches for their detection in clinically relevant specimens, such as serum, plasma, and bronchoalveolar lavage fluid (BALF). The focus is on the design of electrode interfaces, biorecognition components such as antibodies, aptamers, and molecularly imprinted polymers, and signal amplification methods. The limitations of traditional techniques such as ELISA, immunohistochemistry, and PCR are critically analyzed when compared to biosensor techniques. An informatics framework bridging laboratory research and clinical applications is proposed, focusing on AI-assisted informatics for the integration of a multimodal MLKL biomarker panel. This study underscores the potential of electrochemical biosensing as a distinctive approach for developing MLKL-specific necroptosis diagnostics in lung cancer.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Kazmi I, Alzarea SI, Shahwan M, et al. Electrochemical biosensors for MLKL-related necroptosis biomarkers in lung cancer: From bench to clinical laboratory. Clin Chim Acta. 2026. PMID: 42019750. doi:10.1016/j.cca.2026.121022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。